Denis Chem Lab Limited: Kanchan Daga Group Acquires 9.64% Stake Through Off-Market Transaction

Denis Chem Lab Limited has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, regarding the substantial acquisition of shares by Kanchan Daga and persons acting in concert. The acquisition, completed on March 27, 2026, resulted in an aggregate holding of 9.64% of the company's paid-up equity share capital.

Acquisition Details

The off-market transaction involved the acquisition of equity shares by Kanchan Daga as the primary acquirer, along with two family trusts acting as persons acting in concert (PAC). Prior to this acquisition, none of the parties held any shares in Denis Chem Lab Limited.

Acquirer/PAC: Shares Acquired Percentage Holdings Kanchan Daga (Acquirer): 8,02,500 5.78% Varun Daga Family Trust (PAC): 2,67,499 1.93% Shreans Daga Family Trust (PAC): 2,67,499 1.93% Total Aggregate Holdings: 13,37,498 9.64%

Company Share Capital Structure

Denis Chem Lab Limited's equity share capital remains unchanged following the acquisition. The company's share capital structure shows consistent figures across all parameters:

Parameter: Details Paid-up Equity Share Capital: Rs. 13,87,66,680 Total Number of Equity Shares: 1,38,76,668 Face Value per Share: Rs. 10 Stock Exchange Listing: BSE Limited BSE Security Code: 537536

Regulatory Compliance

The disclosure was made in accordance with Regulation 29(1) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Kanchan Daga, holding PAN number ABOPD3647D, confirmed that the acquirer group does not belong to the promoter or promoter group category.

The acquisition involved only equity shares carrying voting rights, with no involvement of warrants, convertible securities, voting rights otherwise than by shares, or any encumbrances such as pledges or liens. The transaction was executed entirely through off-market mechanisms, and the formal disclosure was submitted to both Denis Chem Lab Limited and BSE Limited on March 30, 2026.

Denis chem lab Limited, a manufacturer of parenteral products, announced its unaudited financial results for the quarter ended December 31, 2025, showcasing strong operational performance across key financial metrics. The Board of Directors approved these results during their meeting held on February 14, 2026, under Regulation 33 of SEBI (LODR) Regulations, 2015.

Financial Performance Highlights

The company delivered impressive financial results for Q3FY26, with significant improvements in profitability and revenue growth. Denis Chem Lab demonstrated robust business momentum during the quarter, reflecting effective operational management and market positioning.

Financial Metric: Q3FY26 (₹ Lakh) Q3FY25 (₹ Lakh) Growth (%) Revenue from Operations: 4,551.83 4,284.13 +6.2% Total Income: 4,595.84 4,314.13 +6.5% Net Profit: 332.16 176.14 +88.6% Earnings Per Share: ₹2.39 ₹1.27 +88.2%

Nine-Month Cumulative Performance

For the nine months ended December 31, 2025, Denis Chem Lab maintained strong performance momentum with consistent growth across revenue and profitability parameters.

Parameter: 9M FY26 (₹ Lakh) 9M FY25 (₹ Lakh) Change (%) Revenue from Operations: 13,496.55 13,191.63 +2.3% Total Income: 13,635.27 13,311.86 +2.4% Net Profit: 800.92 736.83 +8.7% Earnings Per Share: ₹5.77 ₹5.31 +8.7%

Board Meeting and Regulatory Compliance

The Board of Directors meeting commenced at 10:00 a.m. and concluded at 12:45 p.m. on February 14, 2026. The results were submitted under Regulation 33 and other applicable provisions of SEBI (LODR) Regulations, 2015. Managing Director Himanshu C. Patel (DIN: 00087114) signed the regulatory filings, confirming compliance with all statutory requirements.

Operational Efficiency and Business Profile

Denis Chem Lab Limited operates exclusively in manufacturing and sales of transfusion solutions in bottles, maintaining focus on its core business segment. The company has no subsidiaries or associates, operating as a standalone entity. The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.

The company maintains a paid-up equity share capital of ₹1,387.67 lakh with face value of ₹10 per share, remaining unchanged from previous periods. The audit committee reviewed these financial results before Board approval, with statutory auditors issuing an unmodified opinion on the quarterly results.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.